Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real‐world data
Sign Up to like & getrecommendations! Published in 2020 at "Hematological Oncology"
DOI: 10.1002/hon.2737
Abstract: The impact of ruxolitinib therapy on evolution to blast phase (BP) in patients with myelofibrosis (MF) is still uncertain. In 589 MF patients treated with ruxolitinib, we investigated incidence and risk factors for BP and… read more here.
Keywords: risk; blast phase; treated ruxolitinib; myelofibrosis ... See more keywords
Allogeneic transplantation for CML blast phase: Learnings over last decade from a single centre in North India
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Hematology"
DOI: 10.1007/s00277-025-06350-w
Abstract: Chronic myeloid leukemia in the blast phase (BP-CML) remains challenging despite advancements in tyrosine kinase inhibitors (TKIs). This study retrospectively assessed BP-CML patients who underwent allogeneic stem cell transplantation (allo-SCT) from June 2009 to December… read more here.
Keywords: post transplant; blast phase; blast; cml ... See more keywords
Sudden blast phase in chronic myeloid leukemia developed during nilotinib therapy after major molecular response was achieved
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Hematology"
DOI: 10.1007/s12185-017-2354-6
Abstract: Sudden blast phase (SBP) is a rare event in which patients with chronic myeloid leukemia (CML) in complete cytogenetic response (CCyR) rapidly progress to the blast phase. Few patients on second-generation tyrosine kinase inhibitors (2nd… read more here.
Keywords: phase; blast phase; response; myeloid leukemia ... See more keywords
Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors.
Sign Up to like & getrecommendations! Published in 2019 at "Biochemical and biophysical research communications"
DOI: 10.1016/j.bbrc.2019.10.067
Abstract: Morphine is an opioid analgesic drug routinely used in the postoperative period for pain management in cancer patients. In this work, we analyzed the effects of morphine on leukemia cells at all stages of development… read more here.
Keywords: blast phase; cml; morphine; leukemia cells ... See more keywords
Outcomes and predictors of survival in blast phase myeloproliferative neoplasms.
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia research"
DOI: 10.1016/j.leukres.2018.05.004
Abstract: We retrospectively reviewed treatment outcomes for 57 patients with myeloproliferative neoplasms in blast phase (MPN-BP). The median overall survival (OS) of the entire cohort was 5.8 months. For patients receiving induction therapy, 67% achieved a… read more here.
Keywords: blast phase; outcomes predictors; predictors survival; myeloproliferative neoplasms ... See more keywords
Blast Phase Chronic Myelomonocytic Leukemia: Mayo-MDACC Collaborative study of 171 cases
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia"
DOI: 10.1038/s41375-018-0143-8
Abstract: Chronic myelomonocytic leukemia (CMML) is a clonal, hematopoietic stem cell disorder, characterized by sustained peripheral blood (PB) monocytosis and an inherent risk for blast phase (BP) disease.1, 2 Blast phase, as defined by ≥20% PB… read more here.
Keywords: phase; blast phase; myelomonocytic leukemia; chronic myelomonocytic ... See more keywords
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry
Sign Up to like & getrecommendations! Published in 2024 at "Leukemia"
DOI: 10.1038/s41375-024-02204-y
Abstract: Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity of the condition and the heterogeneity of the biology and clinical presentation, prospective… read more here.
Keywords: biology; leukemia; blast phase; blast ... See more keywords
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase
Sign Up to like & getrecommendations! Published in 2024 at "Leukemia"
DOI: 10.1038/s41375-024-02425-1
Abstract: Myeloproliferative neoplasms (MPN) are a heterogeneous group of clonal disorders characterized by aberrant hematopoietic proliferation and an intrinsic risk of progression to blast phase. The WHO classification 2022 identifies chronic myeloid leukemia and the BCR::ABL1… read more here.
Keywords: genetics; myeloproliferative neoplasms; blast phase; driver mutations ... See more keywords
Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2023 at "Annals of Medicine"
DOI: 10.1080/07853890.2022.2164611
Abstract: Abstract Background There is a lack of evidence regarding whether combination therapy of hypomethylating agents (HMAs) has better outcomes than HMA monotherapy in patients with Philadelphia chromosome-negative accelerated or blast phase myeloproliferative neoplasms (MPN-AP/BP). Materials… read more here.
Keywords: hypomethylating agents; combination; hmas plus; accelerated blast ... See more keywords
Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2017.1345750
Abstract: Abstract Aims: To evaluate healthcare resource utilization and economic burden of patients with chronic myeloid leukemia (CML) progression to the blast phase. Methods: Patients (≥ 18 years) with ≥1 inpatient or ≥2 outpatient CML diagnoses… read more here.
Keywords: resource utilization; blast phase; healthcare resource; progression blast ... See more keywords
Stachydrine is effective and selective against blast phase chronic myeloid leukaemia through inhibition of multiple receptor tyrosine kinases
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutical Biology"
DOI: 10.1080/13880209.2022.2044862
Abstract: Abstract Context Resistance to BCR-ABL tyrosine kinase inhibitor (TKI) is the cause of treatment failure in blast phase chronic myeloid leukaemia (BP-CML). Agents that act synergistically with BCR-ABL TKI are required to improve response. Objective… read more here.
Keywords: combination; blast phase; myeloid leukaemia; tki ... See more keywords